

Table 19.29
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2005-2011

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)	
Lymphoid Neoplasm	171,838	69.0 (68.7 , 69.3)		89.5 (88.8 , 90.2)		76.6 (76.2 , 76.9)		58.4 (57.9 , 59.0)	
1 Hodgkin Lymphoma	14,979	85.9 (85.2 , 86.6)		97.0 (96.1 , 97.8)		89.9 (89.1 , 90.5)		53.6 (50.5 , 56.5)	
2 Non-Hodgkin lymphoma	152,478	67.8 (67.5 , 68.2)		87.4 (86.5 , 88.2)		74.8 (74.4 , 75.2)		59.2 (58.6 , 59.7)	
2(a) Non-Hodgkin lymphoma, B-cell	140,008	68.3 (67.9 , 68.6)		88.4 (87.4 , 89.3)		75.7 (75.3 , 76.1)		59.8 (59.2 , 60.4)	
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	7,457	68.6 (67.3 , 69.7)		88.2 (87.0 , 89.2)		37.6 (35.2 , 40.0)		16.0 (12.3 , 20.1)	
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	126,080	68.2 (67.9 , 68.6)		88.8 (86.6 , 90.6)		77.1 (76.6 , 77.5)		59.9 (59.4 , 60.5)	
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	30,161	77.6 (76.9 , 78.4)		- (- , -)		86.0 (85.1 , 86.8)		72.0 (70.8 , 73.1)	
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	26,520	80.7 (79.9 , 81.5)		- (- , -)		88.8 (87.9 , 89.7)		75.3 (74.1 , 76.5)	
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	105	43.2 (30.5 , 55.3)		- (- , -)		57.0 (36.0 , 73.5)		35.4 (20.0 , 51.1)	
2(a) 2.1.3. Mantle-cell lymphoma	3,536	55.8 (53.5 , 58.0)		- (- , -)		67.7 (64.7 , 70.6)		45.9 (42.6 , 49.1)	
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	2,736	80.1 (77.4 , 82.5)		- (- , -)		87.6 (84.5 , 90.1)		75.5 (71.6 , 78.9)	
2(a) 2.2.1. Lymphoplasmacytic lymphoma	1,237	74.9 (70.7 , 78.6)		- (- , -)		82.6 (77.3 , 86.8)		70.2 (64.3 , 75.4)	
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,499	84.2 (80.6 , 87.1)		- (- , -)		91.0 (87.2 , 93.7)		79.7 (74.4 , 84.1)	
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	33,046	61.2 (60.6 , 61.9)		87.0 (83.3 , 90.0)		70.7 (69.8 , 71.5)		51.6 (50.5 , 52.6)	
2(a) 2.3.1. DLBCL, NOS ^c	32,657	61.1 (60.4 , 61.8)		88.1 (84.4 , 91.0)		70.5 (69.7 , 71.4)		51.6 (50.5 , 52.7)	
2(a) 2.3.2. Intravascular large B-cell lymphoma	42	51.0 (32.9 , 66.5)		- (- , -)		- (- , -)		- (- , -)	
2(a) 2.3.3. Primary effusion lymphoma	54	22.5 (10.8 , 36.9)		- (- , -)		24.1 (10.4 , 40.9)		- (- , -)	
2(a) 2.3.4. Mediastinal large B-cell lymphoma	293	83.2 (77.5 , 87.6)		- (- , -)		87.8 (82.1 , 91.8)		- (- , -)	
2(a) 2.4. Burkitt lymphoma/leukemia	2,198	59.1 (56.8 , 61.3)		88.7 (85.3 , 91.3)		56.3 (53.3 , 59.1)		33.0 (27.2 , 38.9)	
2(a) 2.5. Marginal-zone lymphoma (MZL)	9,101	89.6 (88.4 , 90.7)		98.4 (89.3 , 99.8)		92.5 (91.2 , 93.6)		86.8 (84.7 , 88.7)	
2(a) 2.5.1. Splenic MZL	787	83.9 (79.1 , 87.7)		- (- , -)		85.4 (79.7 , 89.6)		82.4 (74.3 , 88.1)	
2(a) 2.5.2. Extranodal MZL, MALT ^c type	5,450	94.0 (92.4 , 95.3)		97.5 (83.5 , 99.6)		95.5 (94.1 , 96.7)		92.4 (89.3 , 94.6)	
2(a) 2.5.3. Nodal MZL	2,864	82.8 (80.5 , 85.0)		- (- , -)		87.7 (85.0 , 90.1)		78.4 (74.6 , 81.6)	
2(a) 2.6. Follicular lymphoma	17,933	86.4 (85.5 , 87.1)		94.6 (79.2 , 98.7)		90.9 (90.1 , 91.6)		80.2 (78.6 , 81.8)	
2(a) 2.7. Hairy-cell leukemia	1,460	93.5 (90.9 , 95.5)		- (- , -)		97.4 (95.6 , 98.5)		82.9 (75.0 , 88.6)	
2(a) 2.8. Plasma cell neoplasms	29,416	46.4 (45.6 , 47.2)		- (- , -)		59.5 (58.4 , 60.6)		36.1 (35.0 , 37.2)	
2(a) 2.8.1. Plasmacytoma	1,837	66.6 (63.5 , 69.5)		- (- , -)		78.3 (74.8 , 81.4)		51.0 (45.6 , 56.1)	
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	27,579	45.0 (44.2 , 45.9)		- (- , -)		57.8 (56.7 , 59.0)		35.4 (34.3 , 36.5)	
2(a) 2.9. Heavy chain disease	29	53.1 (28.0 , 73.0)		- (- , -)		- (- , -)		- (- , -)	
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	6,471	69.1 (67.4 , 70.7)		92.6 (82.9 , 96.9)		76.4 (74.2 , 78.4)		64.1 (61.6 , 66.4)	

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.29 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2005-2011

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)	
2(b) Non-Hodgkin lymphoma, T-cell	10,425	64.0 (62.9 , 65.1)		84.2 (81.9 , 86.3)		67.5 (66.1 , 68.9)		50.4 (48.0 , 52.8)	
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	794	64.2 (60.5 , 67.7)		85.0 (80.8 , 88.3)		47.3 (41.4 , 53.0)		10.6 (3.1 , 23.4)	
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	9,567	64.2 (62.9 , 65.4)		83.9 (80.9 , 86.4)		68.9 (67.5 , 70.4)		51.3 (48.8 , 53.7)	
2(b) 2.1. Mycosis fungoides/Sezary syndrome	2,422	89.2 (86.9 , 91.1)		94.7 (76.6 , 98.9)		92.2 (90.0 , 94.0)		82.2 (76.3 , 86.7)	
2(b) 2.1.1. Mycosis fungoides	2,353	90.7 (88.4 , 92.5)		94.7 (76.6 , 98.9)		93.0 (90.9 , 94.7)		85.2 (79.0 , 89.6)	
2(b) 2.1.2. Sezary syndrome	69	34.0 (19.1 , 49.6)		- (- , -)		45.5 (21.8 , 66.5)		25.4 (9.0 , 45.9)	
2(b) 2.2. Peripheral T-cell lymphoma	5,490	57.0 (55.3 , 58.6)		81.4 (75.9 , 85.8)		64.2 (62.2 , 66.2)		43.1 (40.3 , 45.9)	
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	1,866	37.9 (35.2 , 40.7)		60.2 (43.6 , 73.2)		44.9 (41.2 , 48.6)		28.3 (24.2 , 32.6)	
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	716	43.8 (39.3 , 48.1)		- (- , -)		55.4 (48.9 , 61.4)		33.7 (27.6 , 39.9)	
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	81	72.6 (56.6 , 83.5)		- (- , -)		72.4 (52.0 , 85.2)		- (- , -)	
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	1,147	58.4 (55.1 , 61.5)		86.2 (79.6 , 90.8)		62.4 (58.4 , 66.1)		32.8 (26.1 , 39.6)	
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	49	27.3 (14.8 , 41.3)		- (- , -)		33.0 (17.6 , 49.4)		- (- , -)	
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	60	14.4 (6.3 , 25.6)		- (- , -)		16.4 (5.7 , 31.9)		13.2 (3.3 , 29.9)	
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	1,060	82.8 (79.1 , 85.9)		- (- , -)		87.3 (83.3 , 90.4)		75.3 (67.7 , 81.4)	
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	511	90.6 (85.5 , 94.0)		- (- , -)		94.7 (89.6 , 97.3)		81.8 (68.1 , 90.1)	
2(b) 2.3. Adult T-cell leukemia/lymphoma	958	58.4 (54.6 , 62.0)		84.7 (80.7 , 88.0)		37.5 (31.4 , 43.6)		16.3 (8.1 , 27.0)	
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	428	43.1 (37.6 , 48.6)		- (- , -)		42.7 (36.5 , 48.8)		40.6 (27.2 , 53.6)	
2(b) 2.5. T-cell large granular lymphocytic leukemia	120	69.4 (57.1 , 78.8)		- (- , -)		77.8 (59.7 , 88.6)		59.4 (42.0 , 73.1)	
2(b) 2.6. Prolymphocytic leukemia, T-cell	149	13.5 (6.9 , 22.3)		- (- , -)		14.0 (5.4 , 26.8)		13.0 (4.5 , 26.1)	
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	64	38.7 (26.2 , 51.0)		- (- , -)		54.2 (36.4 , 68.9)		- (- , -)	
2(c) Non-Hodgkin lymphoma, unknown lineage	2,045	58.7 (56.2 , 61.1)		84.7 (81.3 , 87.6)		55.1 (50.9 , 59.0)		43.2 (38.7 , 47.5)	
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	914	63.9 (60.5 , 67.1)		85.2 (81.8 , 88.1)		36.1 (29.3 , 42.8)		23.4 (15.7 , 31.9)	
2(c) 2. Prolymphocytic leukemia, unknown lineage	54	50.0 (33.5 , 64.4)		- (- , -)		- (- , -)		41.0 (22.5 , 58.7)	
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	1,077	54.7 (51.0 , 58.3)		- (- , -)		64.7 (59.5 , 69.4)		47.4 (42.2 , 52.4)	
2(*) 1. Total precursor lymphoma/leukemia ^d	9,165	67.8 (66.7 , 68.8)		87.7 (86.7 , 88.6)		38.8 (36.7 , 40.9)		17.3 (14.1 , 20.9)	
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	85	64.4 (50.1 , 75.6)		- (- , -)		71.4 (55.0 , 82.7)		50.5 (25.1 , 71.3)	
4 Lymphoid neoplasm, NOS ^c	4,296	49.3 (47.3 , 51.2)		85.4 (73.9 , 92.2)		61.8 (59.0 , 64.4)		40.1 (37.4 , 42.8)	

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.